EUVIMEDEUVIMED entdecken
Crossref

Platelet NO/ROS Equilibrium—A Novel Mechanism for COVID-19 Related Thrombotic Events?

Eli Israel Lev, Ziv Sevilya iD

Thrombosis and Haemostasis · 01.07.2025 · 125 (07) · 673

DOI: 10.1055/a-2570-9093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.07.2025. Verfasst von Eli Israel Lev und 1 weiteren Autor:innen. Beteiligte Einrichtung: Assuta Ashdod Medical Center and the Ben-Gurion University of the Negev, Ashdod, Israel. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID-19 infection, especially in its severe presentations, has been associated with high incidence of venous and arterial thrombotic complications, mainly venous thromboembolism, myocardial infarction, and ischemic stroke.[ 1 ] [ 2 ] Several mechanisms have been proposed for the elevated risk of thrombotic events including an excessive inflammatory response, platelet activation, intravascular coagulopathy, marked endothelial dysfunction, and stasis.[ 1 ] Virus-induced as well as cytokine-induced platelet, neutrophil, and endothelial cell activation have all been shown to be triggers of a pronounced thrombo-inflammatory cycle leading to the thrombotic events.[ 2 ] Research of the pathways leading to platelet hyper-reactivity in COVID-19 has focused on virus- and cytokine-induced platelet activation, immune complex mediated activation, as well as augmented release of immature hyper-reactive platelets from megakaryocytes.[ 2 ] [ 3 ] In the current issue of Thrombosis and Haemostasis , Petito et al describe a novel platelet mechanism contributing to the elevated risk of thrombotic complications in COVID-19.[ 4 ] Platelets from COVID-19 patients showed a defective balance of nitric oxide (NO)/reactive oxygen species (ROS) production with reduced NO and increased ROS production, compared with healthy controls and ICU patients without COVID-19.[ 4 ] Furthermore, reduced platelet NO was associated with thrombotic events during hospitalization in COVID-19 patients.[ 4 ] Importantly, impaired platelet NO generation and increased platelet-derived ROS have been associated with platelet activation and enhanced oxidative stress in COVID-19 (current study) as well as other infectious and inflammatory disorders. The finding that platelet NO/ROS production imbalance contributes to the elevated risk of thrombotic events in COVID-19 has important clinical implications. Restoration of platelet NO production, as well as attenuation of ROS production by antioxidants, NO donors, NADPH oxidase inhibitors, or statins (shown to increase endothelial NO production), may all improve the NO/ROS equilibrium in patients with COVID-19 and prevent thrombotic complications. Thus, the platelet may be a key therapeutic target in COVID-19 beyond anti-thrombotic treatment. Publication History Received: 31 March 2025 Accepted: 01 April 2025 Article published online: 21 April 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Autor:innen und Institutionen

  • Assuta Ashdod Medical Center and the Ben-Gurion University of the Negev, Ashdod, Israel.

ORCID-Profile: Ziv Sevilya

Zitieren

APA

Lev, E. I., & Sevilya, Z. (2025). Platelet NO/ROS Equilibrium—A Novel Mechanism for COVID-19 Related Thrombotic Events?. Thrombosis and Haemostasis, 125(07), 673. https://doi.org/10.1055/a-2570-9093

Vancouver

Lev EI, Sevilya Z. Platelet NO/ROS Equilibrium—A Novel Mechanism for COVID-19 Related Thrombotic Events?. Thrombosis and Haemostasis. 2025;125(07):673. doi:10.1055/a-2570-9093

BibTeX
@article{Lev2025,
  author = {Lev, Eli Israel and Sevilya, Ziv},
  title = {Platelet NO/ROS Equilibrium—A Novel Mechanism for COVID-19 Related Thrombotic Events?},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {07},
  pages = {673},
  doi = {10.1055/a-2570-9093}
}
Kostenlos starten →